



# Daily News

**STOP Counterfeits!**  
And Increase Your Market Share!

Like :-

Indian corporates lose **21.7%** of their sales to counterfeits!\*  
(Source FICCI) All Copyrights acknowledged

Mr. Rohitt D. Mistry  
9820011569  
www.holotechonline.com

Published by :



**DAY 3**

## News AT A GLANCE



**CPHI and PMEC India helping pharma industry...**

➔ Page No. 16



**AI, IoT, block-chain shaping pharma...**

➔ Page No. 20



**Bioaltus Pharmaceuticals poised for...**

➔ Page No. 24



**How to Commercialize an Advanced...**

➔ Page No. 42

Advertiser Index - Pg 60

# Sustainability takes centre stage on second day of CPHI India expo

LAXMI YADAV, MUMBAI

**P**HARMACEUTICAL stalwarts have underscored the necessity of a multifaceted approach to address significant sustainability issues facing the Indian pharmaceutical and biopharma industries, including energy efficiency, waste reduction, lifecycle assessments, eco-friendly packaging, supplier collaboration and transition to net-zero.

Speaking at a leadership panel discussion on "Addressing the Critical Sustainability Challenges in Indian Pharma & Biopharma" on second day of CPHI India expo in Noida on November 27, the industry captains also highlighted the need for charting the right roadmap towards sustainability with Environmental, Social, and Governance (ESG) goals.

Moderated by Chakravarthi AVPS,

Global Ambassador, World Packaging Organisation, the panel discussion featured Jerome Gnanaprakasam, Vice President, Dr. Reddy's Laboratories; Sunila Sahasrabudhe, Head -ESG Finance, Biocon; Himanshu Gupta-Director Sales - South Asia, Veolia Water Technologies & Solutions; Chand Prasad Ravipati, Head Packaging Development, Aurobindo Pharma.

**CONTINUED ON p8**

**PIOMA** chemicals  
Partnering Through Innovation

We would love to  
**SEE YOU AT!**

**CPHI** India

**NOVEMBER 2024**  
26TH - 27TH-28TH

Scan QR To  
**Pre-Book A Meeting**

**VENUE**  
India Expo Centre,  
Greater Noida, Delhi.

**HALL NO : 08**  
**STALL NO : Q01**

# How to Commercialize an Advanced Therapy: Lessons Learned and Future Plans



DR. SANJAY AGRAWAL

**T**HE commercialization of advanced therapies, such as cell and gene therapies, holds great promise for treating previously incurable diseases. However, these novel therapies present unique challenges in terms of development, production, and distribution. Bringing advanced therapies from the lab to the market requires a deep understanding of regulatory hurdles, supply chain complexities, manufacturing, pricing, and patient access.

This article delves into the critical lessons learned from the commercialization of advanced therapies and discusses future plans for scaling and optimizing this process to meet growing patient demand.

## The Rise of Advanced Therapies

Over the past few years, advanced therapies have transformed the medical landscape. Cell therapies, gene therapies, and tissue-engineered products have brought new hope to patients suffering from rare genetic diseases, cancers, and degenerative conditions. These therapies, categorized as Advanced Therapy Medicinal Products (ATMPs), use groundbreaking technologies to target the root cause of diseases at the molecular level.

While the potential for these therapies is tremendous, their commercialization has been far from straightforward. From early R&D to patient access, advanced therapies require an entirely different approach compared to traditional pharmaceuticals or biologics. The lessons learned in navigating this space are crucial for the continued success of the industry.

## Lesson 1: Streamlining Regulatory Pathways

One of the first hurdles in commercializing advanced therapies is regulatory approval. Given the novelty and complexity of ATMPs, traditional regulatory frameworks are often insufficient to ad-

dress the unique challenges these therapies present. Companies have found that early and proactive engagement with regulatory authorities is critical to navigating this complex landscape.

For example, the U.S. Food and Drug Administration (FDA) and the European

Medicines Agency (EMA) have established specific programs for ATMPs, such as the Regenerative Medicine Advanced Therapy (RMAT) designation in the U.S. and the Priority Medicines (PRIME) scheme in the EU. These programs allow

**CONTINUED ON p43 ▶**

COME PARTNER WITH

## ANTHEM BIOSCIENCES



India's Top Tier, Award Winning, Pharma Products and Research Services Company.



Peptides  
Flow Chemistry  
Oligonucleotides  
High Potent Compounds  
Antibody Drug Conjugates



Medicinal Chemistry  
API development (DoE & QbD)  
Process Chemistry  
Custom Synthesis (mg to ton)  
Analytical (Method Development & Validation)



Biologics / Biosimilars  
(Microbial / Mammalian)  
Clone Development  
Biotransformation  
Enzymes, Nutraceuticals & Probiotics  
Fermentation (mg to ton)



GLP Toxicology Studies  
IND Enabling Studies  
Discovery Biology  
Preclinical - DMPK



Anthem Biosciences Private Limited - Unit I:

No 49, Canara Bank Road, Hosur Rd, Electronics City Phase I, Bommasandra Industrial Area, Bengaluru, Karnataka 560099

Anthem Biosciences Private Limited - Unit II:

Plot No 276-P & 277-P, Survey No-20, Harohalli Industrial Area, Phase II, Near Bannikuppe Village, Kanakapura Taluk, Ramnagar District, Harohalli, Karnataka 562112, India

NeoAnthem Lifesciences Private Limited - Unit III:

313-P,314-P, 318-P, Harohalli Industrial Area, Phase II, Kanakapura Taluk, Ramnagar District, Harohalli, Karnataka, 562112, India

Contact Us:

Tel: 080-6672 4000 | Fax: 080-6672 4020 | bd@anthembio.com | www.anthembio.com

# How to Commercialize an Advanced...

**CONTINUED FROM p42**

for accelerated approval pathways, but they also require companies to engage with regulators early in the process to ensure clinical trial designs meet the necessary standards.

Companies like Spark Therapeutics, which developed Luxturna (a gene therapy for a rare form of blindness), successfully leveraged these accelerated pathways. Early discussions with the FDA helped Spark align its clinical trials with regulatory expectations, leading to the timely approval of the therapy.

**Future Plan: Collaboration with Global Regulators**

As the demand for advanced therapies increases globally, companies must expand their regulatory engagement beyond key markets like the U.S. and Europe. Collaborating with regulators in emerging markets will be essential to make these therapies more accessible. Additionally, harmonizing regulatory requirements across regions could help streamline global approval processes.

**Lesson 2: Overcoming Manufacturing Challenges**

Manufacturing advanced therapies is notoriously complex. Unlike traditional drugs, where chemical synthesis is the primary production method, advanced therapies often require the manipulation of living cells or genes, making the production process much more delicate. Variability in the source material (such as patient-derived cells) and the need for stringent quality control add further complexity.

The scalability of manufacturing is another major challenge. For instance, cell therapies often require personalized manufacturing for each patient, meaning each batch is unique. This "one patient, one batch" approach is time-consuming and costly, posing a barrier to large-scale commercialization.

Companies like Novartis, which developed Kymriah (a CAR-T cell therapy for cancer), have invested heavily in building specialized manufacturing facilities and developing robust processes to ensure product consistency and scalability. However, the high costs of such manufacturing approaches remain a significant barrier to broad commercialization.

rier to broad commercialization.

**Future Plan: Automation and Modular Manufacturing**

Looking ahead, the industry must invest in automation and modular manufacturing to scale advanced therapies efficiently. Automated systems for cell

expansion, gene editing, and quality control could significantly reduce costs and improve consistency. Additionally,

**CONTINUED ON p44**



Explore endless possibilities for formulation development with Azelis! Backed by over 40 years of expertise in the pharmaceutical industry, we offer innovative, tailored solutions to meet your unique needs. As your one-stop partner for Pharmaceuticals and Healthcare, we help you unlock the potential of science in modern pharma. Visit us at **CPhI India 2024, booth R.20**, to connect with our industry experts and discover how our technological expertise, industry insights, and revolutionary ideas can keep you ahead of the competition.

**We offer a comprehensive portfolio of ingredients for Pharmaceuticals & Healthcare**

- Functional & film coating polymers
- Plasticizers
- Lipid based excipients
- Colours and flavours
- Gelling agents for capsules
- Base in ointments & suppositories
- Cellulosic diluents,
- Metallic lubricants,
- Anti-tacking agent (talc)
- Vitamins for pharma
- Child-resistant closures (CRC caps)
- Medical Devices, Dosing Syringes.
- Aluminium tubes.
- Glass bottles

**Proudly partnering with leading ingredient manufacturers:**



Scan to find your inspiration  
visit [explore.azelis.com](http://explore.azelis.com)

**Connect with us now:**  
Email: [Sonali.sheth@azelis.com](mailto:Sonali.sheth@azelis.com)  
Phone: +91 9867522652



Innovation through formulation



# How to Commercialize an Advanced...

CONTINUED FROM p43▶

modular manufacturing platforms that can be easily replicated across different locations will help meet growing global demand.

### Lesson 3: Addressing Supply Chain Complexities

The supply chain for advanced therapies is radically different from traditional pharmaceuticals. With some therapies requiring patient-specific material (such as cells), the supply chain becomes a “vein-to-vein” process, where patient cells are harvested, shipped to manufacturing facilities, manipulated, and then returned to the patient.

This process requires precise coordination to ensure the timely delivery of the therapy, as well as the maintenance of product integrity throughout the journey. Temperature control, transportation logistics, and handling of biologic materials are critical factors that can make or break the success of the therapy.

For example, the commercial success of Gilead’s Yescarta (another CAR-T cell therapy) hinged on establishing a reliable and efficient supply chain. Gilead invested in a global logistics network, including specialized cold-chain transportation, to ensure the therapy could be delivered to patients within a narrow timeframe.

### Future Plan: Digitalized Supply Chain and Data Integration

The future of advanced therapy commercialization will require fully digitalized supply chains, integrating data from collection, manufacturing, and delivery points to create real-time visibility. Digital tools, such as blockchain, can help ensure product traceability and improve the efficiency of the vein-to-vein process. Furthermore, collaborations with third-party logistics providers specializing in cold-chain transportation will become more prevalent to support global distribution.

### Lesson 4: Navigating Pricing and Reimbursement

The cost of developing and manufacturing advanced therapies is exceptionally high, which is reflected in their price tags. For example, Zolgensma, a gene therapy for spinal muscular atrophy, has a list price of over \$2 million. These high prices present a significant challenge for

payers, particularly in publicly funded healthcare systems, and have led to debates around the affordability and value of advanced therapies.

To address these concerns, companies are exploring innovative pricing models. Outcomes-based pricing, where payment is tied to the therapy’s long-term effectiveness, has gained

traction. For instance, Novartis offers outcomes-based contracts for Zolgensma, allowing payers to spread the cost over time or receive refunds if the therapy does not meet specific clinical benchmarks.

### Future Plan: Expanding Innovative Pricing Models

As more advanced therapies enter the market, the industry must continue developing and refining innovative pricing and reimbursement models. Pay-for-performance contracts, subscription-based models, and value-based pricing will become essential tools for ensuring patient access while balancing the financial burden on healthcare systems.




Think Innovations  
Think Us

Meet Us




26th - 28th November, 2024  
India Expo Centre, Greater Noida, Delhi NCR, India  
Hall No. 15, Booth No. B32




### OPHTHALMIC LINE

1. Automatic Bottle Unscrambler Machine with Bottle Feeder.
2. Automatic Monoblock Liquid Filling Insert Plugging & Screw Capping Machine.



### NASAL LINE

1. Automatic Bottle Unscrambler Machine.
2. Automatic Bottle Airjet Cleaning Machine.
3. Automatic Continuous Motion Bottle Filling, Pump Placing & Pressing with Screw Capping Machine.



### MDI FILLING LINE

1. Automatic Can Unscrambler Machine with Can Feeder.
2. Automatic Can Cleaning Machine.
3. Automatic Aerosol Can Filling Machine.
4. Automatic Water Stress Bath.
5. Automatic Two Stage tray Loader.

2204, Phase-IV, Nr. Ramol Cross Road, GIDC, Vatva,  
Ahmedabad - 382 445. Tele. : + 91 79 40307151,  
+91 94261 70923 E-mail : jayesh@harsiddhind.com,  
sales2@harsiddhind.com, contact@harsiddhind.com

www.harsiddhind.com